Recently,
Kunming Pharmaceutical Group's Dihydroartemisinin-Piperaquine Tablet (Ketaifu)
successfully received its first order from the Global Fund to Fight AIDS,
Tuberculosis, and Malaria. As a medication with significant efficacy in the
treatment of malaria, this order not only highlights the high quality and
effectiveness of Ketaifu tablets but also marks an important step for Kunming
Pharmaceutical in the global public health field. It is also a vivid example of
Kunming Pharmaceutical’s commitment to altruism and contributing to the
building of a shared human future.
Looking
ahead, Kunming Pharmaceutical Group will continue its deep exploration in the
anti-malaria field, constantly improving product quality and effectiveness, and
will continue to contribute Chinese wisdom and strength to the global fight
against malaria, working alongside countries worldwide to safeguard human
health and well-being.
